Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic’s Symplicity shows benefits in three-year trial

Medtronic’s Symplicity shows benefits in three-year trial

31st October 2013

Medtronic has announced positive data from Symplicity HTN-2, a study evaluating the long-term benefits offered by its Symplicity renal denervation system.

Three-year results from the study showed that the innovative therapy option was associated with significant and sustained drops in blood pressure, consistent with data previously reported after six, 12 and 24 months.

Symplicity HTN-2 is the first and longest-running randomised and controlled clinical trial of renal denervation, which has been shown to be an effective means of treating uncontrolled hypertension.

It is part of a wider series of Symplicity trials being conducted worldwide, with more than 8,000 patients involved.

Dr Robert Whitbourn, associate professor and director of the cardiovascular research centre at St Vincent's Hospital in Melbourne, said: "This data is an important contribution to the growing body of evidence supporting renal denervation with the Symplicity system as a therapy option for this underserved population."

This comes after Medtronic earlier this week launched the OLIF51 Procedure, a new technique that provides lateral access to all levels of the lower lumbar spine.ADNFCR-8000103-ID-801655637-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.